2026 federal action favors research authorization, not access or rescheduling bills.

Lawmakers think they can pass bills that let scientists study psychedelics more easily — that's a safe, bipartisan vote that most politicians can defend to their home districts. But actually letting patients access psychedelic therapy more freely is still too politically risky for most members of Congress to support. So expect research funding to move, but not patient access.

Research authorization is the lowest-risk bipartisan vote. My caucus can pass it without getting ahead of districts. Access bills carry electoral risk I can't sell yet.